ArticleClinical ophthalmology (Auckland, N.Z.)2008
Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections.
Article in Clinical ophthalmology (Auckland, N.Z.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 79 citations in OpenAlex.
- Comparison of preoperative 5% povidone-iodine plus moxifloxacin versus 5% povidone-iodine alone on ocular surface bacterial flora: protocol for a randomized controlled trial.BMC ophthalmology · 2026Trial
- Biocompatibility and antibacterial properties of ordered PLA fiber membranes fabricated via electrospinning technology.iScience · 2026Article
- Sustained-Release Biodegradable Intracameral Implants Containing Dexamethasone and Moxifloxacin: Development and In Vivo Primary Assessment.Pharmaceutics · 2025Article
- Development of sustained-release extemporaneous moxifloxacin loaded commercial soft hydrogel contact lenses.Heliyon · 2025Article
- Topical Antibiotic Therapy in the Ocular Environment: The Benefits of Using Moxifloxacin Eyedrops.Microorganisms · 2024Review
- Metabolic Rewiring ofMetabolites · 2024Review
- Potential new fluoroquinolone treatments for suspected bacterial keratitis.BMJ open ophthalmology · 2022Review
- Clinical features and microbiology of post-cataract surgery endophthalmitis with and without intracameral moxifloxacin prophylaxis: Endophthalmitis prophylaxis study report 3.Indian journal of ophthalmology · 2022Article
- An ion-paired moxifloxacin nanosuspension eye drop provides improved prevention and treatment of ocular infection.Bioengineering & translational medicine · 2021Article
- Cat Inflicted Eye Injury in a Child.Journal of medical cases · 2021Article
- Evaluation of moxifloxacin-induced cytotoxicity on human corneal endothelial cells.Scientific reports · 2021Article
- Ocular Effects of Glycyrrhizin at Acidic and Neutral pH.Frontiers in cellular and infection microbiology · 2021Article
- Improved Ocular Bioavailability of Moxifloxacin HCl using PLGA Nanoparticles: Fabrication, Characterization,Iranian journal of pharmaceutical research : IJPR · 2021Article
- Moxifloxacin Hydrochloride Electrochemical Detection at Gold Nanoparticles Modified Screen-Printed Electrode.Sensors (Basel, Switzerland) · 2020Article
- Nanoemulsion Based Vehicle for Effective Ocular Delivery of Moxifloxacin Using Experimental Design and Pharmacokinetic Study in Rabbits.Pharmaceutics · 2019Article
- Article
- Comparison of aqueous humour concentration after single high dose versus multiple administration of topical moxifloxacin in rabbits.Indian journal of pharmaceutical sciences · 2014Article
- Effect of low concentrations of benzalkonium chloride on acanthamoebal survival and its potential impact on empirical therapy of infectious keratitis.JAMA ophthalmology · 2013Article
- Moxifloxacin in situ gelling microparticles-bioadhesive delivery system.Results in pharma sciences · 2012Article
- Efficacy and tolerability of a combined gatifloxacin plus prednisolone formulation for topical prophylaxis after LASIK.Clinical ophthalmology (Auckland, N.Z.) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moxifloxacin hydrochloride ophthalmic solution 0.5% (Vigamox((R))) is the ocular formulation/adaptation of moxifloxacin. Moxifloxacin is a broad spectrum 8-methoxyfluoroquinolone which terminates bacterial growth by binding to DNA gyrase (topoisomerase II) and topoisomerase IV, essential bacterial enzymes involved in the replication, translation, repair and recombination of deoxyribonucleic acid. Affinity for both enzymes improves potency and reduces the probability of selecting resistant bacterial subpopulations. Vigamox is a bactericidal, concentration dependent, anti-infective. It is preservative free, and well tolerated with minimal ocular side effects. It provides increased penetration into ocular tissues and fluids with improved activity against Streptococci and Staphylococci species and moderate to excellent activity against clinically relevant, gram-negative ocular pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.